Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial - Wikidata - wikimedia - TriplyDB

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

http://www.wikidata.org/entity/Q35187848

about

What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma Medical treatment of renal cancer: new horizons Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients Therapeutic effects and associated adverse events of multikinase inhibitors in metastatic renal cell carcinoma: A meta-analysis Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.Axitinib in metastatic renal cell carcinoma: single center experience.Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.Axitinib: a review in advanced renal cell carcinoma.Axitinib in metastatic renal cell carcinoma: beyond the second-line setting.Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers.Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.MCPIP1 contributes to clear cell renal cell carcinomas development.Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy.Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.Immune consequences of anti-angiogenic therapyin renal cell carcinoma.Hypertension in malignancy-an underappreciated problem.An update on current management of advanced renal cell cancer, biomarkers, and future directions

P2860

Q26782585-D6ECE1DB-FEBC-4B56-82AE-96EEBE86B5DF Q28066747-8AEB9DA4-FFA5-453C-B248-B44FA487E207 Q28073174-BD47489C-06DB-4ED6-96EF-7E9489F521CD Q28079328-7D6C60A1-3F51-4BBA-893F-C3F593419A53 Q35758408-156D6C24-2EC3-45BD-8061-E47CFBE7AAB9 Q36918281-6B1D7F23-AF7C-48B5-9845-E6DFADFB7995 Q37657679-641219ED-65E6-4D75-B353-C5009D84D3A2 Q38611436-8C233627-DA10-411A-8A13-708D4DB3F492 Q38612808-A2472A73-EAFB-4F7C-8AB9-CE92D1729AFF Q38657787-D88302AA-4FEF-4E98-A4D8-99B8E018CB06 Q38686066-99CA0EE3-B4AE-4402-A021-7F28B856013A Q38754136-98198ED8-9B45-4123-AFBF-D40E1563EA03 Q38755164-E9A8FCC1-36F8-4269-85DE-824A49D8F9E6 Q41022521-8FE91250-E483-447B-B463-2F0FC7ED715E Q42364404-8CBECCE0-0C5E-4158-B1CF-0BE51B1A21F7 Q47123004-F4B78ED9-CB56-459F-A249-D4AA88F44EE4 Q54981236-DC66F6B6-4435-4378-91CF-980F9766207E Q55071881-507F1C49-F706-409A-A9E1-2FADCB9797EB Q56897121-E46038D5-C66B-4F02-9125-DB99FD85008E

P2860

Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

http://www.wikidata.org/entity/Q35187848

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Hypertension among patients wi ...... andomized phase III AXIS trial

@ast

Hypertension among patients wi ...... andomized phase III AXIS trial

@en

type

label

Hypertension among patients wi ...... andomized phase III AXIS trial

@ast

Hypertension among patients wi ...... andomized phase III AXIS trial

@en

prefLabel

Hypertension among patients wi ...... andomized phase III AXIS trial

@ast

Hypertension among patients wi ...... andomized phase III AXIS trial

@en

P1433

Q35187848-99D26F7A-9552-4F5A-A4D6-ADEC8A2F4BE9

P1476

Q35187848-58B63825-982C-46EF-AD23-786CEE411B60

P2093

Q35187848-1C75597F-5E94-47B8-BAEE-FD3A2D7ACB6B

Q35187848-3EAF2711-568D-4568-BA82-0DE090896CE1

Q35187848-6B6E0B1D-ACAD-4DE9-9C41-002BAE941704

Q35187848-98BD2ACB-1187-4FC0-B3C8-6CE5B0F73405

Q35187848-9F21FE38-C040-400C-84B7-29D9C90CD552

Q35187848-A188A836-098F-4526-BA03-0C7186F1F942

Q35187848-E635C613-FAF0-472E-90BA-0A099AEC50D6

Q35187848-ED00BD80-6E46-4343-ABC0-179917DA9C58

Q35187848-F044C9A1-86A3-4CB4-A78B-2C2304249349

P2860

Q35187848-02201AFA-43B0-4BC0-A5AB-2C1C31F5CC94

Q35187848-1070C617-93ED-494C-B83B-BB686AA78D38

Q35187848-18989BD3-63D5-4F3A-9E18-1114F535E6BC

Q35187848-302261C3-4635-4CD1-95C7-F1463647A914

Q35187848-32290F43-8457-4CE3-B18A-5F4F4DC619F1

Q35187848-33FF8DB3-20A8-49AB-8B24-1EE91D3CB2BE

Q35187848-46CA3DA4-C751-4CF8-B00B-D78F560D2D8C

Q35187848-4A10750D-ECFE-4961-925E-189D58031053

Q35187848-4AF5CF41-B709-4E0A-9A5D-E9102A70A34E

Q35187848-59D05A79-C93B-434B-BC48-CFE7E7E011E5

P2888

Q35187848-6DC34D3F-BA0B-4B53-98B0-1615329920EB

P304

Q35187848-1D503E4C-0623-4A08-B9A9-C8FC40BFA3A0

P31

Q35187848-CC9EA340-9603-4E72-81B9-089E269AD899

P356

Q35187848-A9C8DD6F-5F4E-4543-9A41-53F86D2678A5

P433

Q35187848-687B7DED-6955-4CCD-A82A-A80B4089AC9B

P478

Q35187848-A6D696B3-590F-4ECB-819E-BD94F57D9460

P50

Q35187848-00875C80-DA1C-4184-A076-9DCE35803CED

Q35187848-A337A11A-8AC2-40F1-8835-BF64C6E2BA1A

P577

Q35187848-EFE8A5C3-50B2-4295-92EF-8EB971ED5435

P5875

Q35187848-D20A9A8D-E0FD-4CB1-8141-BB113582C407

P698

Q35187848-CAE9BB84-26F1-456C-B978-F2E28AAF122A

P921

Q35187848-757E4437-FB72-4E3E-A8C4-D18049DE00EB

P932

Q35187848-6DC17C47-78BA-442C-922E-D8FCB35B9897

P356

S11523-014-0307-Z

P1433

Targeted oncology

P1476

Hypertension among patients wi ...... andomized phase III AXIS trial

@en

P2093

Brad Rosbrook

http://www.w3.org/2001/XMLSchema#string

Brian I Rini

http://www.w3.org/2001/XMLSchema#string

Jamal Tarazi

http://www.w3.org/2001/XMLSchema#string

Laura Cisar

http://www.w3.org/2001/XMLSchema#string

Laura S Wood

http://www.w3.org/2001/XMLSchema#string

Lillian Shahied Arruda

http://www.w3.org/2001/XMLSchema#string

Michael Baum

http://www.w3.org/2001/XMLSchema#string

Sinil Kim

http://www.w3.org/2001/XMLSchema#string

W Gregory Roberts

http://www.w3.org/2001/XMLSchema#string

P2860

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

Sorafenib in advanced clear-cell renal-cell carcinoma

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association

P2888

s11523-014-0307-z

P304

45-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11523-014-0307-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260528110

http://www.w3.org/2001/XMLSchema#string

P698

24595903

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4363524

http://www.w3.org/2001/XMLSchema#string